ClinicalTrialsFinder
RecruitingEarly Phase 1NCT06345898

Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)

Clinical Study on the Safety and Efficacy of JWK002 Injection Administered as a Single Subretinal Injection in Subjects With X-linked Retinoschisis

Sponsor

West China Hospital

Enrollment

12 participants

Start Date

Nov 17, 2023

Study Type

INTERVENTIONAL

Conditions

X-linked Retinoschisis

Summary

This trial is to evaluate the safety and efficacy of JWK002 treatment of X-linked retinoschisis(XLRS). This study will enroll subjects aged 5-18 years old to receive a sub-retinal injection of JWK002.

Eligibility

Sex: MALEMin Age: 5 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JWK002 for people with x-linked retinoschisis. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 5 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJWK002

Subretinal administration of gene therapy vector JWK002 to one eye.

Locations(1)

West China Hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06345898

Related Trials

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

NCT058788604 locations

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

NCT075026641 location

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

NCT058149521 location